Global private equity firm Warburg Pincus has acquired Integrace Private Ltd, a pharmaceuticals company specializing in orthopedics and gynecology, for approximately ₹1,000 crore. The acquisition was announced on Wednesday, and Rehan Khan, a former managing director at MSD and Abbott India, has been appointed as the new chief executive officer to lead the company’s growth strategy.
Key Details
As part of the deal, existing shareholders True North and Temasek will exit their investments in Integrace. Warburg plans to expand its pharmaceutical platform, with potential future acquisitions including Koye Pharma and Maneesh Pharma, according to a source familiar with the matter. Integrace has developed a portfolio of over 20 brands targeting high-growth markets in pain management, pregnancy, and women’s health.
Background
Himanshu Nema, managing director at Warburg Pincus, stated,
Integrace has built an exceptional foundation with a differentiated portfolio in orthopedics and gynecology… This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India.
Integrace has established a network of over 45,000 healthcare professionals across India, supported by a strong base of specialist prescribers.
Related coverage: Stripe and Advent Offer $53 Billion for PayPal Acquisition.
The acquisition may influence investor sentiment in the Indian pharmaceuticals sector, particularly in companies focused on women's health and orthopedic therapies. Warburg Pincus' entry could lead to increased competition and innovation in these segments. Investors will watch for further announcements regarding Warburg's plans for additional acquisitions in the sector.